Zusammenfassung
Die Therapie der Primären ZNS Lymphome (PZNSL) ist in Deutschland uneinheitlich, weil es keine verbindliche Behandlungsempfehlung gibt. Systemisches Hochdosis Methotrexat (MTX) ist zwar ein wesentlicher Therapiebestandteil, MTX allein führt jedoch nach den in Deutschland gemachten Erfahrungen nur bei etwa der Hälfte der Patienten zu einer Remission. Ob MTX durch eine Strahlentherapie oder durch weitere Chemotherapeutika ergänzt werden muss, um die Therapie zu verbessern, ist Gegenstand kontroverser Diskussion und prospektiver Therapiestudien. Wegen der großen Gefahr neurotoxischer Langzeitfolgen nach Hochdosis MTX und Radiatio bei Patienten über 60 Jahre favorisieren die Autoren eine Polychemotherapie ohne Bestrahlung.
Therapy of Primary CNS Lymphoma
Therapy of primary CNS lymphoma (PCNSL) is not yet established. The introduction of systemic high-dose methotrexate (MTX) in its treatment has been a therapeutic breakthrough. However, according to German experience, high dose MTX alone achieves remissions only in about half of the patients. If MTX has to be supplemented by other cytostatic drugs or if it has to be combined with subsequent whole brain radiotherapy in order to improve treatment outcome is a matter of debate and is investigated in ongoing prospective trials in Germany. Since neurotoxic long-term effects are frequent and severe after combined MTX-chemotherapy and radiotherapy in patients over 60 years of age, the authors favor the systematic evaluation of „chemotherapy alone” protocols in this disease.
Literatur
-
1
Paulus W.
Classification, pathogenesis and molecular pathology of primary CNS lymhomas.
J Neuro-Oncol.
1999;
43
203-208
-
2
Schlegel U, Schmidt-Wolf I GH, Deckert M.
Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment.
J Neurol Sci.
2000;
181
1-12
-
3
Fine H A, Mayer R J.
Primary central nervous system lymphoma.
Ann Intern Med.
1993;
119
1093-1104
-
4
Bataille B, Delwail V, Menet E. et al .
Primary intracerebral malignant lymphoma: Report of 248 cases.
J Neurosurg.
2000;
92
261-266
-
5
Ferreri A JM, Reni M, Villa E.
Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trials.
Ann Oncol.
2000;
11
927-937
-
6
Cote T R, Manns A, Hardy C R. et al .
Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome.
J Natl Cancer Inst.
1996;
88
675-679
-
7
Eby N L, Grufferman S, Flannely C M. et al .
Increasing incidence of primary brain lymphoma in the U.S.
Cancer.
1988;
62
2461-2465
-
8
Camilleri-Broet S, Davi F, Feuillard J. et al .
The French Study Group for HIV-Associated Tumors. AIDS-related primary brain lymphomas: histopathological and immunohistochemial study of 51 cases.
Hum Pathol.
1997;
28
367-374
-
9
Nelson D F.
Radiotherapy in the treatment of primary central nervos system lymphoma (PCNSL).
J Neuro-Oncol.
1999;
43
241-247
-
10
Nelson D F, Martz K L, Bonner H. et al .
Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.
Int J Radiat Oncol Biol Phys.
1992;
23
9-17
-
11
Schultz C, Scott C, Sherman W. et al .
Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group Protocol 88-06.
J Clin Oncol.
1996;
14
556-564
-
12
Glass J, Gruber M L, Cher L. et al .
Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome.
J Neurosurg.
1994;
81
188-195
-
13
DeAngelis L M, Yahalom J, Thaler H AT. et al .
Combined modality therapy for primary central nervous system lymphoma.
J Clin Oncol.
1992;
10
635-243
-
14
Hiraga S, Arita N, Ohnishi T. et al .
Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
J Neurosurg.
1999;
91
221-230
-
15
O'Brien P, Roos D, Pratt G. et al .
Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma.
J Clin Oncol.
2000;
18
519-226
-
16
Abrey L E, DeAngelis L M, Yahalom J.
Long-term survival in primary CNS lymphoma.
J Clin Oncol.
1998;
16
859-863
-
17
Blay J-Y, Conroy T, Chevreau C. et al .
High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series.
J Clin Oncol.
1998;
16
864-871
-
18
Guha-Thakurta N, Damek D, Pollak C. et al .
Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients.
J Neuro-Oncol.
1999;
43
259-68
-
19
Sandor V, Stark-Vancs V, Pearson D. et al .
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
J Clin Oncol.
1998;
16
3000-3006
-
20
McAllister L D, Doolittle N D, Guastadisegni P E. et al .
Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
Neurosurgery.
2000;
46
51-59
-
21
Kommentare zu (20).
Neurosurgery.
2000;
46
59-61
-
22
Schlegel U, Pels H, Oehring R. et al .
Neurologic sequelae of treatment of primary CNS lymphomas.
J Neuro-Oncol.
1999;
43
277-286
-
23
Abrey L E, Yahalom J, DeAngelis L M.
Treatment for primary CNS lymphoma: the next step.
J Clin Oncol.
2000;
18
3144-3150
-
24 Ferreri A JM, Reni M, Pasini F. et al .Therapeutic management of immunocompetent patients with primary central nervous system lymphoma (PCNSL): analysis of an international multicentre series of 378 patients. San Francisco; 42nd Meeting American Society of Hematology Dec. 1 - 5, 2000 abstract 2186
-
25 Weller M. Ongoing clinical studies in Germany: NOA-3 study. Clinical workshop: Therapy of primary cerebral NHL. Saarbrücken; Lymphoma 2000 Sept 24 - 27, 2000
-
26 Korfel A. Ongoing clinical studies in Germany: BMPD study. Clinical workshop: Therapy of primary cerebral NHL. Saarbrücken; Lymphoma 2000 Sept 24 - 27, 2000
-
27 Thiel E, Weller M. Phase-IV-Studie zum Stellenwert der Ganzhirnbestrahlung in der Primärtherapie primärer ZNS-Lymphome mit Hochdosis Methotrexat. Berlin; 2000
-
28
Illerhaus G, Marks R, Frickhofen N. et al .
High-dose methotrexate followed by dose-escalated alkylating agents with autologous PBSCT and hyperfractionated radiotherapy as first-line treatment for primary CNS lymphoma (PCNSL) - a multicenter phase II study.
Onkologie.
2000;
23, Suppl 7
0178
-
29
Schlegel U, Pels H, Glasmacher A. et al .
Kombinierte Hochdosis-Polychemotherapie als effiziente alleinige Behandlung primär zerebraler Lymphome.
Akt Neurol.
1998;
25
297-303
-
30
Reni M, Ferreri A J, Villa E.
Second-line treatment for primary central nervous system lymphoma.
Brit J Cancer.
1999;
79
530-534
-
31
Donahue B R, Sullivan J W, Cooper J S.
Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma.
Cancer.
1995;
76
328-332
-
32
Chamberlain M C, Kormanick P A.
AIDS-related central nervous system lymphomas.
J Neuro-Oncol.
1999;
43
269-76
-
33
Forsyth P A, Yaholom J, DeAngelis L M.
Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS.
Neurology.
1994;
44
1473-1478
-
34
Hoang-Xuan K, Delattre J Y.
Ongoing protocols for non-AIDS primary central nervous system lymphoma.
J Neurooncol.
1999;
43
287-291
Prof. Dr. med. Uwe Schlegel
Neurologische Universitätsklinik Bonn
Sigmund-Freud-Straße 25
53105 Bonn
Email: uwe.schlegel@uni-bonn.de
